Allergan Rebuffs Valeant and Agrees to US$66 B Actavis Deal
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 12 (Table of Contents)
Published: 3 Dec-2014
DOI: 10.3833/pdr.v2014.i12.2081 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In the biggest deal of 2014 so far, Allergan has agreed to be acquired by Actavis for US$66 B after staving off the hostile advances of Valeant Pharmaceuticals International and activist investor Pershing Square...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS